Tropanol | 911648-75-4

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: Tropanol
• 英文别名: tropine；8-methyl-8-azabicyclo[3.2.1]octan-3-ol
• CAS: 911648-75-4
• 化学式: C₈H₁₅NO
• mdl: MFCD00180667
• 分子量: 141.213
• InChiKey: CYHOMWAPJJPNMW-UHFFFAOYSA-N

物化性质

• 沸点：
  233.0±0.0 °C(Predicted)
• 密度：
  1.078±0.06 g/cm3(Predicted)
• 熔点：
  86.5 °C
• 保留指数：
  1183;1180;1167;1193

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Tropanol 生成 pseudotropine
  参考文献：
  名称：

  DE128855

  摘要：

  公开号：
• 作为产物：
  描述：

  atropine 在 盐酸 作用下， 生成 Tropanol
  参考文献：
  名称：

  Kraut, Justus Liebigs Annalen der Chemie, 1865, vol. 133, p. 96

  摘要：

  DOI：

文献信息

• Npy antagonists, preparation and uses
  申请人：Botez Iuliana

  公开号：US20090233910A1

  公开（公告）日：2009-09-17

  The present invention concerns novel compounds, their preparation and their uses, therapeutic uses in particular. More specifically it concerns derivative compounds having at least two aromatic cycles, their preparation and their uses, in particular in the area of human or animal health. These compounds have an affinity for the biological receptors of neuropeptide Y, NPY, present in the central and peripheral nervous systems. The compounds of the invention are preferably NPY antagonists, and more particularly antagonists of sub-type NPY Y1, and can therefore be used for the therapeutic or prophylactic treatment of any disorder involving NPY. The present invention also concerns pharmaceutical compositions containing said compounds, their preparation and their uses, as well as treatment methods using said compounds.

  本发明涉及新颖化合物，它们的制备和用途，特别是在治疗方面的用途。更具体地说，它涉及至少具有两个芳香环的衍生化合物，它们的制备和用途，特别是在人类或动物健康领域。这些化合物对存在于中枢和外周神经系统中的神经肽Y（NPY）的生物受体具有亲和力。本发明的化合物优选为NPY拮抗剂，更具体地说是NPY Y1亚型的拮抗剂，因此可用于治疗或预防涉及NPY的任何疾病。本发明还涉及含有所述化合物的药物组合物，其制备和用途，以及使用所述化合物的治疗方法。
• Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
  申请人：——

  公开号：US20030069170A1

  公开（公告）日：2003-04-10

  Pharmaceutical compositions that include a drug-oligomer conjugate, a fatty acid component, and a bile salt component are described. The drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1. Methods of treating diseases in a subject in need of such treatment using such pharmaceutical compositions are also provided, as are methods of providing such pharmaceutical compositions.

  描述了包括药物-寡聚物共轭物、脂肪酸成分和胆盐成分的药物组合物。药物以共价键连接到寡聚物基团上。脂肪酸成分和胆盐成分以1:5至5:1的重量比存在。还提供了利用这种药物组合物治疗需要此类治疗的受试者的方法，以及提供这种药物组合物的方法。
• [EN] 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES<br/>[FR] 2 -ARYLAMINOQUINAZOLINES DESTINÉES AU TRAITEMENT DES MALADIES PROLIFÉRATIVES
  申请人：NOVARTIS AG

  公开号：WO2009153313A1

  公开（公告）日：2009-12-23

  The invention provides novel compounds that are inhibitors of PDKI. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or composition.

  这项发明提供了一种抑制PDKI的新型化合物。还提供了包括这些化合物的药物组合物，以及使用这些化合物或组合物治疗增殖性疾病，如癌症的方法。
• [EN] SPIRO[CYCLOPENTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS<br/>[FR] DÉRIVÉS SPIRO[CYCLOPENTANE-1,3'-INDOLIN]-2'-ONE UTILISÉS EN TANT QU'INHIBITEURS DE BROMODOMAINES
  申请人：AURIGENE DISCOVERY TECH LTD

  公开号：WO2018109650A1

  公开（公告）日：2018-06-21

  The present invention provides spiro[cyclopentaneane-1,3'-indolin]-2'-one derivatives of formula (I), which are therapeutically useful, more particularly as bromodomain inhibitors. (I) wherein Cy, R1, R2, L and 'm' have the meaning given in the specification, and pharmaceutically acceptable salts or pharmaceutically acceptable stereoisomers thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use as bromodomain inhibitors in the treatment and prevention of the associated diseases or disorders. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the spiro[cyclopentane-1,3'-indolin]-2'-one derivatives of formula (I), together with a pharmaceutically acceptable carrier, diluent or excipient therefore.

  本发明提供了式(I)的螺[环戊烷-1,3'-吲哚]-2'-酮衍生物，其在治疗上具有用途，更具体地作为溴结构域抑制剂。其中Cy、R1、R2、L和'm'在说明书中给出的含义，以及它们的药学上可接受的盐或药学上可接受的立体异构体，在治疗和预防疾病或紊乱方面具有用途，特别是它们作为溴结构域抑制剂在治疗和预防相关疾病或紊乱方面的用途。本发明还提供了该化合物的制备以及包括至少一种式(I)的螺[环戊烷-1,3'-吲哚]-2'-酮衍生物的药物配方，以及药学上可接受的载体、稀释剂或赋形剂。
• Enantioselective hydrolysis of various racemic α-substituted arylacetonitriles using Rhodococcus sp. CGMCC 0497
  作者：Zhong-Liu Wu、Zu-Yi Li

  DOI：10.1016/s0957-4166(02)00017-4

  日期：2001.12

  The enantioselective hydrolysis of 17 racemic α-substituted arylacetonitriles by Rhodococcus sp. CGMCC 0497 is described. The corresponding (R)-amides and (S)-acids were obtained with excellent enantiomeric excess in most cases. The effect of steric and electronic factors on the outcome of the reactions are discussed here. The results prove that nitrile-converting enzymes are efficient tools for the

  Rhodococcus sp。对映体选择性水解17种外消旋的α-取代的芳基乙腈。描述了CGMCC 0497。在大多数情况下，以优异的对映体过量获得相应的（R）-酰胺和（S）-酸。此处讨论了空间和电子因素对反应结果的影响。结果证明腈转化酶是用于合成空间上不受阻碍的手性α-芳基丙酸和酰胺的有效工具。

表征谱图